1
|
Ou K, Gide DN, El-Den S, Kouladjian O'Donnell L, Malone DT, O'Reilly CL. Pharmacist-led screening for mental illness: A systematic review. Res Social Adm Pharm 2024; 20:828-845. [PMID: 38866605 DOI: 10.1016/j.sapharm.2024.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 05/29/2024] [Accepted: 06/05/2024] [Indexed: 06/14/2024]
Abstract
BACKGROUND Early identification and treatment of mental illnesses is imperative for optimal patient outcomes. Pharmacists may play an important role in mental healthcare through the provision of screening services for mental illnesses. OBJECTIVE (s): To systematically review the impact of pharmacist-led mental illness screening on clinical or patient-reported outcomes and identify and report any follow-up or referral systems used in pharmacist-led screening interventions for mental illnesses. METHODS A systematic review was conducted by searching MEDLINE, CINAHL, Embase and APA PsycInfo via EBSCOhost from inception to 9 March 2023 to identify studies involving pharmacist-led screening interventions for mental illnesses. Data was collected on the mental illness in question, setting and population characteristics, screening tools used, clinical or patient-reported outcomes, and follow-up and referral systems reported. RESULTS Twenty six studies were identified that related to screening for mental illnesses, such as depressive disorders and substance use disorders. There were a variety of study designs, including uncontrolled studies (n = 23), pre-post studies (n = 2) and randomised controlled trials (n = 1). Screening was conducted in different settings, with most studies conducted in community pharmacies (n = 21/26, 87.8 %) and focusing on depression screening (n = 12/26, 46.1 %). A range of follow-up and referral methods to other healthcare professionals were reported, including verbal (n = 3/26, 11.5 %), both written and verbal (n = 3/26, 11.5 %), communications via electronic health record (n = 2/26, 7.7 %) and written (n = 1/26, 3.8 %). CONCLUSIONS Pharmacists provide screening for a variety of mental illnesses in different settings. Various referral methods and follow-up pathways may be utilised for post-screening patient care. However, current evidence is insufficient to establish improvements in early detection, treatment, or outcomes. Further large, well-designed studies are required to support the role of pharmacists in mental illness screening, provide evidence on the impact of pharmacist-led mental illness screening services and inform the most effective follow up and referral methods.
Collapse
Affiliation(s)
- Kevin Ou
- Pharmaceutical Society of Australia, Sydney, NSW, Australia
| | - Duha N Gide
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
| | - Sarira El-Den
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Lisa Kouladjian O'Donnell
- Clinical Pharmacology and Ageing, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia
| | - Daniel T Malone
- Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia
| | - Claire L O'Reilly
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
2
|
Ho JL, Roberts J, Payne GH, Holzum DN, Wilkoff H, Tran T, Cobb CD, Moore TD, Lee KC. Systematic literature review of the impact of psychiatric pharmacists. Ment Health Clin 2024; 14:33-67. [PMID: 38312443 PMCID: PMC10836561 DOI: 10.9740/mhc.2024.02.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Accepted: 12/01/2023] [Indexed: 02/06/2024] Open
Abstract
Introduction Pharmacists focusing on psychotropic medication management and practicing across a wide variety of healthcare settings have significantly improved patient-level outcomes. The Systematic Literature Review Committee of the American Association of Psychiatric Pharmacists was tasked with compiling a comprehensive database of primary literature highlighting the impact of psychiatric pharmacists on patient-level outcomes. Methods A systematic search of literature published from January 1, 1961, to December 31, 2022, was conducted using PubMed and search terms based on a prior American Association of Psychiatric Pharmacists literature review. Publications describing patient-level outcome results associated with pharmacist provision of care in psychiatric/neurologic settings and/or in relation to psychotropic medications were included. The search excluded articles for which there was no pharmacist intervention, no psychiatric disorder treatment, no clinical outcomes, no original research, no access to full text, and/or no English-language version. Results A total of 4270 articles were reviewed via PubMed, with 4072 articles excluded based on title, abstract, and/or full text in the initial pass and 208 articles selected for inclusion. A secondary full-text review excluded 11 additional articles, and 5 excluded articles were ultimately included based on a secondary review, for a final total of 202 articles meeting the inclusion criteria. A comprehensive database of these articles was compiled, including details on their study designs and outcomes. Discussion The articles included in the final database had a wide range of heterogeneity. While the overall impact of psychiatric pharmacists was positive, the study variability highlights the need for future publications to have more consistent, standardized outcomes with stronger study designs.
Collapse
Affiliation(s)
- Jessica L Ho
- Clinical Pharmacist, St. Peter Regional Treatment Center, St. Peter, Minnesota
- Director of Strategic Initiatives, American Association of Psychiatric Pharmacists, Lincoln, Nebraska
- Pain Management/Substance Use Disorder Clinical Pharmacy Practitioner, VISN 20 Clinical Resource Hub, Boise, Idaho
- Clinical Pharmacy Specialist- Behavioral Health, Adventist HealthCare Shady Grove Medical Center, Rockville, Maryland
- Medical Science Liaison, Medical Affairs, Braeuburn, Plymouth Meeting, Pennsylvania; Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois
- Founder and Consultant, Capita Consulting, Billings, Montana
- National Program Manager, Clinical Pharmacy, Clinical Practice Integration and Model Advancement Pharmacy Benefits Management (PBM), Colorado
- Professor of Clinical Pharmacy, University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California
| | - Jenna Roberts
- Clinical Pharmacist, St. Peter Regional Treatment Center, St. Peter, Minnesota
| | - Gregory H Payne
- Director of Strategic Initiatives, American Association of Psychiatric Pharmacists, Lincoln, Nebraska
| | - Dorothy N Holzum
- Pain Management/Substance Use Disorder Clinical Pharmacy Practitioner, VISN 20 Clinical Resource Hub, Boise, Idaho
| | - Hannah Wilkoff
- Clinical Pharmacy Specialist- Behavioral Health, Adventist HealthCare Shady Grove Medical Center, Rockville, Maryland
| | - Tran Tran
- Medical Science Liaison, Medical Affairs, Braeuburn, Plymouth Meeting, Pennsylvania; Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois
| | - Carla D Cobb
- Founder and Consultant, Capita Consulting, Billings, Montana
| | - Tera D Moore
- National Program Manager, Clinical Pharmacy, Clinical Practice Integration and Model Advancement Pharmacy Benefits Management (PBM), Colorado
| | - Kelly C Lee
- Professor of Clinical Pharmacy, University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California
| |
Collapse
|
3
|
Rao D, Mercy M, McAtee C, Ford JH, Shiyanbola OO. A scoping literature review of pharmacy-based opioid misuse screening and brief interventions. Res Social Adm Pharm 2023:S1551-7411(23)00253-X. [PMID: 37210240 PMCID: PMC10186861 DOI: 10.1016/j.sapharm.2023.05.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 04/04/2023] [Accepted: 05/08/2023] [Indexed: 05/22/2023]
Abstract
BACKGROUND Although prescription opioid dispensing rates have continued to decrease, overdose deaths involving prescription opioids have increased during the COVID-19 pandemic. Screening and brief interventions (SBI) are an effective prevention strategy to identify and address opioid misuse and safety risks. Emerging literature on pharmacy-based SBI needs to be systematically appraised to develop robust interventions. OBJECTIVE Our objective was to conduct a scoping review of the literature regarding pharmacy-based opioid misuse SBI to identify relevant literature that explore the topic, evaluate the patient-centeredness of included studies, and explore the use of dissemination and implementation science in the literature. METHODS The review was conducted according to Preferred Reporting of Systematic Reviews and Meta-analyses -Scoping reviews (PRISMA-Sc) guidelines. We searched PubMed, CINHAL, PsychInfo, and Scopus for studies regarding pharmacy-based SBI, published in the last 20 years. We also conducted a separate grey literature search. Two of three total reviewers screened each abstract individually and identified eligible full-texts for inclusion. We critically appraised quality of included studies and qualitatively synthesized the relevant information. RESULTS The search resulted in 21 studies (categorized as intervention, descriptive, and observational research) and 3 grey literature reports. Of the recently published 21 studies, 11 were observational research, with six interventions in the pilot stages. Screening tools varied but naloxone was the brief intervention in 15 of the 24 results. Only eight studies had high validity, reliability, and applicability and only five were patient-centered. Implementation science principles were addressed in eight studies (mainly interventions). Overall, the findings suggest high potential for evidence-based SBI to be successful. CONCLUSIONS Overall, the review suggested a strong lack of a patient-centered and implementation science-focused approach to designing pharmacy-based opioid misuse SBI. Findings suggest that a patient-centered, implementation focused approach is needed for effective and sustained pharmacy-based opioid misuse SBI.
Collapse
Affiliation(s)
- Deepika Rao
- School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53703, USA.
| | - Meg Mercy
- University of Wisconsin-Madison, Madison, WI, USA.
| | | | - James H Ford
- School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53703, USA.
| | - Olayinka O Shiyanbola
- School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53703, USA.
| |
Collapse
|